X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Receives $9.70 Consensus PT from Analysts

Shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) have been assigned a consensus rating of “Moderate Buy” from the seven brokerages that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $9.70.

A number of research analysts have recently issued reports on the company. Weiss Ratings lowered X4 Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, July 10th. Wells Fargo & Company initiated coverage on X4 Pharmaceuticals in a research note on Friday, July 10th. They set an “overweight” rating and a $11.00 price target for the company. Finally, Leerink Partners assumed coverage on X4 Pharmaceuticals in a report on Tuesday, June 2nd. They set an “outperform” rating and a $12.00 price target for the company.

X4 Pharmaceuticals Stock Performance

NASDAQ XFOR opened at $3.94 on Friday. The company has a quick ratio of 9.98, a current ratio of 10.18 and a debt-to-equity ratio of 0.45. X4 Pharmaceuticals has a 52-week low of $1.35 and a 52-week high of $4.83. The business’s 50-day moving average price is $4.00 and its 200 day moving average price is $3.93. The firm has a market cap of $371.62 million, a P/E ratio of -0.87 and a beta of 0.35.

X4 Pharmaceuticals (NASDAQ:XFOR) last issued its quarterly earnings results on Wednesday, May 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.04. X4 Pharmaceuticals had a negative return on equity of 94.90% and a negative net margin of 1,106.30%.The firm had revenue of $2.71 million for the quarter, compared to analysts’ expectations of $3.20 million. On average, equities research analysts expect that X4 Pharmaceuticals will post -0.77 earnings per share for the current year.

Insider Transactions at X4 Pharmaceuticals

In other X4 Pharmaceuticals news, CFO David Kirske sold 8,543 shares of the company’s stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $4.26, for a total transaction of $36,393.18. Following the completion of the transaction, the chief financial officer owned 167,750 shares in the company, valued at approximately $714,615. This represents a 4.85% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 1.13% of the company’s stock.

Institutional Trading of X4 Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in XFOR. Perceptive Advisors LLC purchased a new position in X4 Pharmaceuticals during the fourth quarter worth about $25,258,000. Empery Asset Management LP purchased a new stake in X4 Pharmaceuticals in the 4th quarter valued at approximately $35,804,000. Charles Schwab Investment Management Inc. purchased a new stake in X4 Pharmaceuticals in the 4th quarter valued at approximately $267,000. Acorn Capital Advisors LLC increased its position in X4 Pharmaceuticals by 77.8% during the 3rd quarter. Acorn Capital Advisors LLC now owns 273,349 shares of the company’s stock worth $935,000 after purchasing an additional 119,619 shares during the period. Finally, Braidwell LP acquired a new position in X4 Pharmaceuticals during the 4th quarter worth approximately $13,476,000. Hedge funds and other institutional investors own 72.03% of the company’s stock.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.